NurExone Biologic (FRA:J90) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. NurExone Biologic's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. NurExone Biologic's average Total Assets over the quarter that ended in Dec. 2024 was €2.79 Mil. Therefore, NurExone Biologic's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

NurExone Biologic Gross-Profit-to-Asset % Historical Data

The historical data trend for NurExone Biologic's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Gross-Profit-to-Asset % Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of NurExone Biologic's Gross-Profit-to-Asset %

For the Biotechnology subindustry, NurExone Biologic's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

NurExone Biologic Gross-Profit-to-Asset % Calculation

NurExone Biologic's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0	/	( (1.99	+	2.331)	/ 2 )
	=	0	/	2.1605
	=	0.00 %

NurExone Biologic's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (3.256	+	2.331)	/ 2 )
	=	0	/	2.7935
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

NurExone Biologic Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

NRXBF:USA NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines